Melanoma, version 2.2016 - Clinical Practice Guidelines in Oncology Journal Article
| Authors: | Coit, D. G.; Thompson, J. A.; Algazi, A.; Andtbacka, R.; Bichakjian, C. K.; Carson, W. E., III; Daniels, G. A.; DiMaio, D.; Ernstoff, M.; Fields, R. C.; Fleming, M. D.; Gonzalez, R.; Guild, V.; Halpern, A. C.; Hodi, F. S., Jr.; Joseph, R. W.; Lange, J. R.; Martini, M. C.; Materin, M. A.; Olszanski, A. J.; Ross, M. I.; Salama, A. K.; Skitzki, J.; Sosman, J.; Swetter, S. M.; Tanabe, K. K.; Torres-Roca, J. F.; Trisal, V.; Urist, M. M.; McMillian, N.; Engh, A. |
| Article Title: | Melanoma, version 2.2016 - Clinical Practice Guidelines in Oncology |
| Abstract: | This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and highdose ipilimumab. Treatment options for in-transit disease now include intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted reassessment of the data supporting older recommended treatment options for adjuvant therapy and in-transit disease, resulting in extensive revisions to the supporting discussion sections. © 2016 National Comprehensive Cancer Network, Inc. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 14 |
| Issue: | 4 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2016-04-01 |
| Start Page: | 450 |
| End Page: | 473 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 27059193 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 June 2016 -- Source: Scopus |
Citation Impact
Related MSK Work